Details of the Drug

General Information of Drug (ID: DMKOXFE)

Drug Name
Doxylamine
Synonyms
Dossilamina; Doxilamina; Doxilminio; Doxylaminum; Dossilamina [DCIT]; Diclectin (TN); Dolased (TN); Donormyl (TN); Dormidina (TN); Doxilminio [INN-Spanish]; Doxylamine (INN); Doxylamine [INN:BAN]; Doxylaminum [INN-Latin]; Dozile (TN); Evanorm (TN); Mersyndol (TN); Restavit (TN); Somnil (TN); Syndol (TN); Unisom-2 (TN); Phenyl-2-pyridylmethyl-beta-N,N-dimethylaminoethyl ether; N,N-Dimethyl-2-(1-phenyl-1-(2-pyridinyl)ethoxy)ethanamine; N,N-dimethyl-2-(1-phenyl-1-pyridin-2-ylethoxy)ethanamine; N,N-dimethyl-2-[(1-phenyl-1-pyridin-2-ylethyl)oxy]ethanamine; N,N-dimethyl-2-[1-phenyl-1-(pyridin-2-yl)ethoxy]ethanamine; 2-(alpha-(2-(Dimethylamino)ethoxy)-alpha-methylbenzyl)pyridine; 2-Dimethylaminoethoxyphenylmethyl-2-picoline
Indication
Disease Entry ICD 11 Status REF
Allergic rhinitis CA08.0 Approved [1]
Common cold CA00 Approved [1]
Morning sickness SC00 Approved [2]
Seasonal allergic rhinitis CA08.01 Approved [1]
Urticaria EB00-EB05 Approved [1]
Vasomotor/allergic rhinitis CA08 Approved [1]
Pruritus EC90 Investigative [1]
⏷ Show the Full List of Indication(s)
Therapeutic Class
Hypnotics and Sedatives
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 270.37
Logarithm of the Partition Coefficient (xlogp) 2.5
Rotatable Bond Count (rotbonds) 6
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
Absorption
The drug is readily absorbed from the gastrointestinal tract []
Half-life
The concentration or amount of drug in body reduced by one-half in 10 hours [3]
Metabolism
The drug is metabolized via the hepatic []
Chemical Identifiers
Formula
C17H22N2O
IUPAC Name
N,N-dimethyl-2-(1-phenyl-1-pyridin-2-ylethoxy)ethanamine
Canonical SMILES
CC(C1=CC=CC=C1)(C2=CC=CC=N2)OCCN(C)C
InChI
InChI=1S/C17H22N2O/c1-17(20-14-13-19(2)3,15-9-5-4-6-10-15)16-11-7-8-12-18-16/h4-12H,13-14H2,1-3H3
InChIKey
HCFDWZZGGLSKEP-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
3162
ChEBI ID
CHEBI:51380
CAS Number
469-21-6
DrugBank ID
DB00366
TTD ID
D0Y2LR
ACDINA ID
D00216
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Histamine H1 receptor (H1R) TTTIBOJ HRH1_HUMAN Antagonist [4]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Phosphatidylcholine translocator ABCB4 (ABCB4) OTE6PY83 MDR3_HUMAN Gene/Protein Processing [5]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Allergic rhinitis
ICD Disease Classification CA08.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Histamine H1 receptor (H1R) DTT HRH1 6.74E-01 0.13 0.43
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Doxylamine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Methylene blue DMJAPE7 Major Additive CNS depression effects by the combination of Doxylamine and Methylene blue. Acquired methaemoglobinaemia [3A93] [6]
Scopolamine DMOM8AL Moderate Additive anticholinergic effects by the combination of Doxylamine and Scopolamine. Addictive disorder [6C50-6C5Z] [7]
Mepyramine DMB4SFH Moderate Additive anticholinergic effects by the combination of Doxylamine and Mepyramine. Allergic/hypersensitivity disorder [4A80-4A8Z] [8]
Phenyltoloxamine DMKAEQW Moderate Additive anticholinergic effects by the combination of Doxylamine and Phenyltoloxamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [8]
Tripelennamine DMZBU15 Moderate Additive anticholinergic effects by the combination of Doxylamine and Tripelennamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [7]
Tacrine DM51FY6 Moderate Antagonize the effect of Doxylamine when combined with Tacrine. Alzheimer disease [8A20] [9]
Memantine DMD9WSC Moderate Additive anticholinergic effects by the combination of Doxylamine and Memantine. Alzheimer disease [8A20] [7]
Galantamine DMEO794 Moderate Antagonize the effect of Doxylamine when combined with Galantamine. Alzheimer disease [8A20] [9]
Rivastigmine DMG629M Moderate Antagonize the effect of Doxylamine when combined with Rivastigmine. Alzheimer disease [8A20] [9]
Donepezil DMIYG7Z Moderate Antagonize the effect of Doxylamine when combined with Donepezil. Alzheimer disease [8A20] [9]
Hydroxyzine DMF8Y74 Moderate Additive anticholinergic effects by the combination of Doxylamine and Hydroxyzine. Anxiety disorder [6B00-6B0Z] [7]
Promazine DMZAL7W Moderate Additive anticholinergic effects by the combination of Doxylamine and Promazine. Appearance/behaviour symptom [MB23] [7]
Desipramine DMT2FDC Moderate Additive anticholinergic effects by the combination of Doxylamine and Desipramine. Attention deficit hyperactivity disorder [6A05] [7]
Linezolid DMGFPU2 Major Additive anticholinergic effects by the combination of Doxylamine and Linezolid. Bacterial infection [1A00-1C4Z] [6]
Cariprazine DMJYDVK Moderate Additive anticholinergic effects by the combination of Doxylamine and Cariprazine. Bipolar disorder [6A60] [7]
Loperamide DMOJZQ9 Moderate Additive antimotility effects by the combination of Doxylamine and Loperamide. Bowel habit change [ME05] [10]
Acetylcholine DMDF79Z Moderate Antagonize the effect of Doxylamine when combined with Acetylcholine. Cataract [9B10] [11]
Umeclidinium DM4E8O9 Moderate Additive anticholinergic effects by the combination of Doxylamine and Umeclidinium. Chronic obstructive pulmonary disease [CA22] [12]
Tiotropium DMFDC0Q Moderate Additive anticholinergic effects by the combination of Doxylamine and Tiotropium. Chronic obstructive pulmonary disease [CA22] [12]
Revefenacin DMMP5SI Moderate Additive anticholinergic effects by the combination of Doxylamine and Revefenacin. Chronic obstructive pulmonary disease [CA22] [12]
Olopatadine DMKMWQG Moderate Additive CNS depression effects by the combination of Doxylamine and Olopatadine. Conjunctiva disorder [9A60] [13]
Ethanol DMDRQZU Moderate Additive CNS depression effects by the combination of Doxylamine and Ethanol. Cystitis [GC00] [13]
Trimipramine DM1SC8M Moderate Additive anticholinergic effects by the combination of Doxylamine and Trimipramine. Depression [6A70-6A7Z] [7]
Cyclobenzaprine DM1YBRM Moderate Additive anticholinergic effects by the combination of Doxylamine and Cyclobenzaprine. Depression [6A70-6A7Z] [7]
Imipramine DM2NUH3 Moderate Additive anticholinergic effects by the combination of Doxylamine and Imipramine. Depression [6A70-6A7Z] [7]
Nortriptyline DM4KDYJ Moderate Additive anticholinergic effects by the combination of Doxylamine and Nortriptyline. Depression [6A70-6A7Z] [7]
Selegiline DM6034S Major Additive anticholinergic effects by the combination of Doxylamine and Selegiline. Depression [6A70-6A7Z] [6]
Isocarboxazid DMAF1NB Major Additive anticholinergic effects by the combination of Doxylamine and Isocarboxazid. Depression [6A70-6A7Z] [6]
Tranylcypromine DMGB5RE Major Additive CNS depression effects by the combination of Doxylamine and Tranylcypromine. Depression [6A70-6A7Z] [6]
OPC-34712 DMHG57U Moderate Additive anticholinergic effects by the combination of Doxylamine and OPC-34712. Depression [6A70-6A7Z] [7]
Phenelzine DMHIDUE Major Additive CNS depression effects by the combination of Doxylamine and Phenelzine. Depression [6A70-6A7Z] [6]
Amoxapine DMKITQE Moderate Additive anticholinergic effects by the combination of Doxylamine and Amoxapine. Depression [6A70-6A7Z] [7]
Doxepin DMPI98T Moderate Additive anticholinergic effects by the combination of Doxylamine and Doxepin. Depression [6A70-6A7Z] [7]
Maprotiline DMPWB7T Moderate Additive anticholinergic effects by the combination of Doxylamine and Maprotiline. Depression [6A70-6A7Z] [7]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Doxylamine and Esketamine. Depression [6A70-6A7Z] [14]
Hyoscyamine DM804UR Moderate Additive anticholinergic effects by the combination of Doxylamine and Hyoscyamine. Digestive system disease [DE2Z] [7]
Mepenzolate DM8YU2F Moderate Additive anticholinergic effects by the combination of Doxylamine and Mepenzolate. Digestive system disease [DE2Z] [7]
Oxybutynine DMJPBAX Moderate Additive anticholinergic effects by the combination of Doxylamine and Oxybutynine. Discovery agent [N.A.] [7]
Meclizine DMS7T13 Moderate Additive anticholinergic effects by the combination of Doxylamine and Meclizine. Dizziness and giddiness [MB48] [7]
Trihexyphenidyl DMB19L8 Moderate Additive anticholinergic effects by the combination of Doxylamine and Trihexyphenidyl. Dystonic disorder [8A02] [7]
Zonisamide DM0DTF7 Major Increased risk of hyperpyrexia by the combination of Doxylamine and Zonisamide. Epilepsy/seizure [8A61-8A6Z] [15]
Diphenhydramine DMKQTBA Moderate Additive anticholinergic effects by the combination of Doxylamine and Diphenhydramine. Episodic vestibular syndrome [AB31] [7]
Solifenacin DMG592Q Moderate Additive anticholinergic effects by the combination of Doxylamine and Solifenacin. Functional bladder disorder [GC50] [7]
Tolterodine DMSHPW8 Moderate Additive anticholinergic effects by the combination of Doxylamine and Tolterodine. Functional bladder disorder [GC50] [7]
Darifenacin DMWXLYZ Moderate Additive anticholinergic effects by the combination of Doxylamine and Darifenacin. Functional bladder disorder [GC50] [7]
Propantheline DM2EN6G Moderate Additive anticholinergic effects by the combination of Doxylamine and Propantheline. Gastric ulcer [DA60] [7]
Isoflurophate DMBSK7X Moderate Antagonize the effect of Doxylamine when combined with Isoflurophate. Glaucoma [9C61] [11]
Brimonidine DMQLT4N Moderate Additive CNS depression effects by the combination of Doxylamine and Brimonidine. Glaucoma [9C61] [16]
Procarbazine DMIK367 Major Additive CNS depression effects by the combination of Doxylamine and Procarbazine. Hodgkin lymphoma [2B30] [6]
Potassium chloride DMMTAJC Major Increased risk of GI mucosal injury/bleeding risk by the combination of Doxylamine and Potassium chloride. Hypo-kalaemia [5C77] [17]
Belladonna DM2RBWK Moderate Additive anticholinergic effects by the combination of Doxylamine and Belladonna. Infectious gastroenteritis/colitis [1A40] [7]
Amantadine DMS3YE9 Moderate Additive anticholinergic effects by the combination of Doxylamine and Amantadine. Influenza [1E30-1E32] [18]
Propiomazine DMKY8V1 Moderate Additive anticholinergic effects by the combination of Doxylamine and Propiomazine. Insomnia [7A00-7A0Z] [7]
ITI-007 DMUQ1DO Moderate Additive anticholinergic effects by the combination of Doxylamine and ITI-007. Insomnia [7A00-7A0Z] [7]
Clidinium DMUMQZ0 Moderate Additive anticholinergic effects by the combination of Doxylamine and Clidinium. Irritable bowel syndrome [DD91] [7]
Dicyclomine DMZSDGX Moderate Additive anticholinergic effects by the combination of Doxylamine and Dicyclomine. Irritable bowel syndrome [DD91] [7]
Physostigmine DM2N0TO Moderate Antagonize the effect of Doxylamine when combined with Physostigmine. Lips/oral mucosa miscellaneous disorder [DA02] [9]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Doxylamine and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [19]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Doxylamine and Lasmiditan. Migraine [8A80] [20]
Thalidomide DM70BU5 Moderate Additive CNS depression effects by the combination of Doxylamine and Thalidomide. Multiple myeloma [2A83] [21]
Ozanimod DMT6AM2 Major Additive anticholinergic effects by the combination of Doxylamine and Ozanimod. Multiple sclerosis [8A40] [22]
Phenindamine DMDTC7R Moderate Additive anticholinergic effects by the combination of Doxylamine and Phenindamine. Nasopharyngitis [CA00] [7]
Dimenhydrinate DM264B3 Moderate Additive anticholinergic effects by the combination of Doxylamine and Dimenhydrinate. Nausea/vomiting [MD90] [7]
Prochlorperazine DM53SRA Moderate Additive anticholinergic effects by the combination of Doxylamine and Prochlorperazine. Nausea/vomiting [MD90] [7]
Promethazine DM6I5GR Moderate Additive anticholinergic effects by the combination of Doxylamine and Promethazine. Nausea/vomiting [MD90] [7]
Cyclizine DM9G7BS Moderate Additive anticholinergic effects by the combination of Doxylamine and Cyclizine. Nausea/vomiting [MD90] [7]
Thiethylperazine DMU3IET Moderate Additive anticholinergic effects by the combination of Doxylamine and Thiethylperazine. Nausea/vomiting [MD90] [7]
Levomethadyl Acetate DM06HG5 Major Additive CNS depression effects by the combination of Doxylamine and Levomethadyl Acetate. Opioid use disorder [6C43] [23]
Apraclonidine DMO4PVE Moderate Additive CNS depression effects by the combination of Doxylamine and Apraclonidine. Optic nerve disorder [9C40] [16]
Dextropropoxyphene DM23HCX Major Additive CNS depression effects by the combination of Doxylamine and Dextropropoxyphene. Pain [MG30-MG3Z] [24]
Flavoxate DMKV4NL Moderate Additive anticholinergic effects by the combination of Doxylamine and Flavoxate. Pain [MG30-MG3Z] [7]
Biperiden DME78OA Moderate Additive anticholinergic effects by the combination of Doxylamine and Biperiden. Parkinsonism [8A00] [7]
Procyclidine DMHFJDT Moderate Additive anticholinergic effects by the combination of Doxylamine and Procyclidine. Parkinsonism [8A00] [7]
Orphenadrine DMW542E Moderate Additive anticholinergic effects by the combination of Doxylamine and Orphenadrine. Parkinsonism [8A00] [7]
Methylscopolamine DM5VWOB Moderate Additive anticholinergic effects by the combination of Doxylamine and Methylscopolamine. Peptic ulcer [DA61] [7]
Levomepromazine DMIKFEL Moderate Additive anticholinergic effects by the combination of Doxylamine and Levomepromazine. Psychotic disorder [6A20-6A25] [7]
Fluphenazine DMIT8LX Moderate Additive anticholinergic effects by the combination of Doxylamine and Fluphenazine. Psychotic disorder [6A20-6A25] [7]
Triflupromazine DMKFQJP Moderate Additive anticholinergic effects by the combination of Doxylamine and Triflupromazine. Psychotic disorder [6A20-6A25] [7]
Cyproheptadine DM92AH3 Moderate Additive anticholinergic effects by the combination of Doxylamine and Cyproheptadine. Rheumatoid arthritis [FA20] [7]
Quetiapine DM1N62C Moderate Additive anticholinergic effects by the combination of Doxylamine and Quetiapine. Schizophrenia [6A20] [7]
Mesoridazine DM2ZGAN Moderate Additive anticholinergic effects by the combination of Doxylamine and Mesoridazine. Schizophrenia [6A20] [7]
Thioridazine DM35M8J Moderate Additive anticholinergic effects by the combination of Doxylamine and Thioridazine. Schizophrenia [6A20] [7]
Aripiprazole DM3NUMH Moderate Additive anticholinergic effects by the combination of Doxylamine and Aripiprazole. Schizophrenia [6A20] [7]
Iloperidone DM6AUFY Moderate Additive anticholinergic effects by the combination of Doxylamine and Iloperidone. Schizophrenia [6A20] [7]
Paliperidone DM7NPJS Moderate Additive anticholinergic effects by the combination of Doxylamine and Paliperidone. Schizophrenia [6A20] [7]
Loxapine DM8AI9U Moderate Additive anticholinergic effects by the combination of Doxylamine and Loxapine. Schizophrenia [6A20] [7]
Haloperidol DM96SE0 Moderate Additive anticholinergic effects by the combination of Doxylamine and Haloperidol. Schizophrenia [6A20] [7]
Perphenazine DMA4MRX Moderate Additive anticholinergic effects by the combination of Doxylamine and Perphenazine. Schizophrenia [6A20] [7]
Molindone DMAH70G Moderate Additive anticholinergic effects by the combination of Doxylamine and Molindone. Schizophrenia [6A20] [7]
Chlorpromazine DMBGZI3 Moderate Additive anticholinergic effects by the combination of Doxylamine and Chlorpromazine. Schizophrenia [6A20] [7]
Thiothixene DMDINC4 Moderate Additive anticholinergic effects by the combination of Doxylamine and Thiothixene. Schizophrenia [6A20] [7]
Trifluoperazine DMKBYWI Moderate Additive anticholinergic effects by the combination of Doxylamine and Trifluoperazine. Schizophrenia [6A20] [7]
Risperidone DMN6DXL Moderate Additive anticholinergic effects by the combination of Doxylamine and Risperidone. Schizophrenia [6A20] [7]
Asenapine DMSQZE2 Moderate Additive anticholinergic effects by the combination of Doxylamine and Asenapine. Schizophrenia [6A20] [7]
Pimozide DMW83TP Moderate Additive anticholinergic effects by the combination of Doxylamine and Pimozide. Schizophrenia [6A20] [7]
Tizanidine DMR2IQ4 Moderate Additive CNS depression effects by the combination of Doxylamine and Tizanidine. Tonus and reflex abnormality [MB47] [25]
Atropine DMEN6X7 Moderate Additive anticholinergic effects by the combination of Doxylamine and Atropine. Unspecific substance harmful effect [NE6Z] [7]
Chlorpheniramine DM5URA2 Moderate Additive anticholinergic effects by the combination of Doxylamine and Chlorpheniramine. Vasomotor/allergic rhinitis [CA08] [7]
Triprolidine DM7SWIA Moderate Additive anticholinergic effects by the combination of Doxylamine and Triprolidine. Vasomotor/allergic rhinitis [CA08] [7]
Methdilazine DMAUHQX Moderate Additive anticholinergic effects by the combination of Doxylamine and Methdilazine. Vasomotor/allergic rhinitis [CA08] [7]
Carbinoxamine DMCT31R Moderate Additive anticholinergic effects by the combination of Doxylamine and Carbinoxamine. Vasomotor/allergic rhinitis [CA08] [7]
Trimeprazine DMEMV9D Moderate Additive anticholinergic effects by the combination of Doxylamine and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [8]
Brompheniramine DMFOVSD Moderate Additive anticholinergic effects by the combination of Doxylamine and Brompheniramine. Vasomotor/allergic rhinitis [CA08] [7]
Dexbrompheniramine DMKVWGE Moderate Additive anticholinergic effects by the combination of Doxylamine and Dexbrompheniramine. Vasomotor/allergic rhinitis [CA08] [7]
Acrivastine DMTIGA0 Moderate Additive anticholinergic effects by the combination of Doxylamine and Acrivastine. Vasomotor/allergic rhinitis [CA08] [7]
Azatadine DMZ80SB Moderate Additive anticholinergic effects by the combination of Doxylamine and Azatadine. Vasomotor/allergic rhinitis [CA08] [7]
⏷ Show the Full List of 106 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
FD&C blue no. 1 E00263 19700 Colorant
Quinoline yellow WS E00309 24671 Colorant
Sucralose E00370 71485 Flavoring agent
Tannic acid E00517 16129778 Antioxidant
Brushite E00392 104805 Diluent
Calcium hydrogenphosphate E00294 24441 Diluent
Magnesium stearate E00208 11177 lubricant
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Water E00035 962 Solvent
⏷ Show the Full List of 10 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Doxylamine 5 mg tablet 5 mg Chewable Tablet Oral
Doxylamine 25 mg tablet 25 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Doxylamine FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7171).
3 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4 First-generation H1 antihistamines found in pilot fatalities of civil aviation accidents, 1990-2005. Aviat Space Environ Med. 2007 May;78(5):514-22.
5 Evaluating the Role of Multidrug Resistance Protein 3 (MDR3) Inhibition in Predicting Drug-Induced Liver Injury Using 125 Pharmaceuticals. Chem Res Toxicol. 2017 May 15;30(5):1219-1229. doi: 10.1021/acs.chemrestox.7b00048. Epub 2017 May 4.
6 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
7 Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
8 Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
9 Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32. [PMID: 1888249]
10 Eronen M, Putkonen H, Hallikainen T, Vartiainen H "Lethal gastroenteritis associated with clozapine and loperamide." Am J Psychiatry 160 (2003): 2242-2243. [PMID: 14638602]
11 Multum Information Services, Inc. Expert Review Panel.
12 Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
13 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
14 Cerner Multum, Inc. "Australian Product Information.".
15 Product Information. Zonegran (zonisamide) Elan Pharmaceuticals, S. San Francisco, CA.
16 Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
17 Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206. [PMID: 1148734]
18 Postma JU, van Tilburg W "Visual hallucinations and delirium during treatment with amantadine (Symmetrel)." J Am Geriatr Soc 23 (1975): 212-5. [PMID: 123540]
19 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
20 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
21 Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
22 Alvine G, Black DW, Tsuang D "Case of delirium secondary to phenelzine/L-tryptophan combination." J Clin Psychiatry 51 (1990): 311. [PMID: 2365671]
23 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
24 Hansen BS, Dam M, Brandt J, et al "Influence of dextropropoxyphene on steady state serum levels and protein binding of three anti-epileptic drugs in man." Acta Neurol Scand 61 (1980): 357-67. [PMID: 6998251]
25 Product Information. Zanaflex (tizanidine). Acorda Therapeutics, Hawthorne, NY.